SNDX (STOCKS)
Syndax Pharmaceuticals, Inc.
$24.010000
-0.430000 (-1.76%)
Prev close: $24.440000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Michael A. Metzger
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,137.98M
- Employees
- 184
- P/E (TTM)
- -7.41
- P/B (TTM)
- 33.05
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
8
Strong Buy
11
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.78 | $-0.60 | -0.1842 | -30.92% |
|
Sep 2025 (Q3)
|
$-0.70 | $-0.73 | +0.0310 | +4.24% |
|
Jun 2025 (Q2)
|
$-0.83 | $-1.04 | +0.2064 | +19.92% |
|
Mar 2025 (Q1)
|
$-0.98 | $-1.36 | +0.3773 | +27.80% |
Financial Statements
| Revenues | $172.35M |
| Benefits Costs and Expenses | $0.00 |
| Costs And Expenses | $445.44M |
| Nonoperating Income/Loss | -$12.34M |
| Operating Expenses | $445.44M |
| Selling, General, and Administrative Expenses | $179.68M |
| Research and Development | $258.78M |
| Other Operating Expenses | $6.97M |
| Operating Income/Loss | -$273.08M |
| Income/Loss From Continuing Operations After Tax | -$285.42M |
| Income/Loss From Continuing Operations Before Tax | $172.35M |
| Income Tax Expense/Benefit | $433.00K |
| Net Income/Loss | -$285.42M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$285.42M |
| Net Income/Loss Available To Common Stockholders, Basic | -$285.42M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.29 |
| Diluted Earnings Per Share | -$3.29 |
| Basic Average Shares | 86,625,610 |
| Diluted Average Shares | 86,625,610 |
| Assets | $529.71M |
| Current Assets | $528.08M |
| Inventory | $32.75M |
| Other Current Assets | $495.33M |
| Noncurrent Assets | $1.63M |
| Fixed Assets | $181.00K |
| Other Non-current Assets | $1.44M |
| Liabilities | $465.08M |
| Current Liabilities | $120.12M |
| Accounts Payable | $16.58M |
| Wages | $24.35M |
| Other Current Liabilities | $79.18M |
| Noncurrent Liabilities | $344.96M |
| Equity | $64.63M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $64.63M |
| Liabilities And Equity | $529.71M |
| Net Cash Flow From Operating Activities | -$322.98M |
| Net Cash Flow From Operating Activities, Continuing | -$322.98M |
| Net Cash Flow From Investing Activities | $290.04M |
| Net Cash Flow From Investing Activities, Continuing | $290.04M |
| Net Cash Flow From Financing Activities | $13.68M |
| Net Cash Flow From Financing Activities, Continuing | $13.68M |
| Net Cash Flow | -$19.27M |
| Net Cash Flow, Continuing | -$19.27M |
| Comprehensive Income/Loss | -$285.13M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$285.13M |
| Other Comprehensive Income/Loss | $289.00K |